1Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection[J]. N Engl J Med, 1998, 338(13): 853-860.
2Grulich AE. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy[J]. J Acquir Immune Defic Syndr, 1999, 21(Suppl 1): S27-S30.
3Kovacs J, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection[J]. N Engl J Med, 2000, 342(19): 1416-1429.
4Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression:results from the EuroSIDA study[J]. Ann Intern Med, 1999, 130(7): 570-577.
5Nielsen H, Kvinesdal B, Benfield T, et al. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection[J]. Scand J Infect Dis, 1998, 30(6): 597-601.
6Tasker SA, Treanor JJ, Paxton WB, et al. Efficacy of influenza vaccination in HIV-infceted persons: a randomized ,double-blind, placebo-controlled trial[J]. Ann Intern Med, 1999, 131(6): 430-433.
7Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabution, or both[J]. N Engl J Med, 1996, 335(6): 392-398.
8McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study[J]. Clin Infect Dis, 1999, 28(5): 1049-1056.
9Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy[J]. N Engl J Med, 1999, 340(17): 1301-1306.
10Kirk O, Lundgren JD, Pedersen C, et al. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy[J]. AIDS, 1999,13(13): 1647-1651.
4Kovacs J, Massur H. Prophylaxis against to opportunistic infections inpatients with human immunodeficiency virus infection. N Engl J Med,2000,342(19) :1416-1429.
5Wannamethee SG, Sirivichayakul S, Phillips AN, et al. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand. Int J Epidemiol,1998,27(2):289-295.
6Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir antiretroviral therapy, and HIV-1 disease progression: results from the euro AIDS study. Ann Intern Med, 1999,130(7) :570- 577.
7Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-assoclated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis, 2000,30 Suppl 1 : S5-14.
8Dore GJ,Hoy JF, Mallal SA, et al. Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort. J Acquit Immune Defic Syndr Hum Retrovirol, 1997,16 (1) :39-43.
9Maartens G,Wood R, O' Keefe E, et al. Independent epidemics of heterosexual and homosexual HIV infection in South Africa- survival differences. Q J Med, 1997,90(7) :449- 454.
10Yazdanpanah Y,Chene G, Losina E, et al. Incidence of primary opportunistic infections in two human immunodeficiency virus infected French clinical cohorts. Int J Epidemiol, 2001,30 (4) : 864-871.